Initial Pushita results encouraging:
This article was originally published in Clinica
The results of the first phase of MicroSense International's human feedback trial of its Pushita blood glucose monitor (see Clinica No 913, p 17) have shown less than 5% variation when compared with "the leading blood glucose monitor". Pushita measures the concentration of glucose in interstitial fluid, rather than blood, which means that sampling is less painful for the patient. MicroSense's objective now is to complete the trial and find a strategic partner to bring the product to market.